CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
September 2022—BD and Accelerate Diagnostics announced a worldwide commercial collaboration agreement in which BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility. Under the agreement, BD will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its worldwide sales network in territories where products have regulatory approval or registration.
The Accelerate PhenoTest BC kit is an FDA-cleared test that can deliver both rapid identification and phenotypic antibiotic susceptibility results in hours, direct from positive blood cultures. The Accelerate Arc module is a novel application of inline centrifugal and sample preparation techniques that provide a suspension of cleaned and concentrated microbial cells which, together with the blood culture kit, allow for direct transfer to a MALDI spotting plate. According to Accelerate, independent studies show the BC kit provides identification and susceptibility results with minimum inhibitory concentrations about 40 hours faster than current methods.